1 Article

2 3 4

5 6

7

Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy and venous thromboembolism

Grant Castaneda^{1,2,†}, Abby C Lee^{1,2,†}, Wei Tse Li^{1,2}, Chengyu Chen^{1,2}, Jaideep Chakladar^{1,2}, Eric Y. Chang³, and Weg M. Ongkeko^{1,2,*}

- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California, San Diego, La Jolla, California, United States of America
- 8 9 ² Research Service, VA San Diego Healthcare System, San Diego, California, CA, 92161, US
- 10 3 Department of Radiology, University of California, San Diego, California CA, 92093, USA
- 11 * Correspondence: rongkeko@health.ucsd.edu; Tel.: (858) 552-8585 X 7165
- 12 [†] Authors contributed equally

13

14 Abstract

As of 28 August 2020, there have been 5.88 million Coronavirus Disease 2019 (COVID-15 16 19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an 17 effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its 18 varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown 19 20 that there is a higher prevalence of cardiovascular comorbidities amongst patients with severe 21 COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease and poorer 22 prognosis is poorly understood. We believe that pre-existing immune dysregulation that accompanies cardiovascular disease predisposes patients to a harmful inflammatory immune 23 response, leading to their higher risk of severe disease. Thus, in this project, we aim to 24 characterize immune dysregulation in patients with cardiomyopathy, venous thromboembolism 25 and COVID-19 patients by looking at immune-associated gene dysregulation, immune infiltration 26 27 and dysregulated immunological pathways and gene signatures.

28

29 **Keywords:** COVID-19; cardiovascular disease; cardiomyopathy; venous thromboembolism

30 1. Introduction

In December 2019, widespread infection by severe acute respiratory syndrome 31 coronavirus 2 (SARS-CoV-2), was reported in Wuhan, Hubei Province, China [1]. Since then, 32 SARS-CoV-2 has spread rapidly throughout China and across the world and was declared a 33 global pandemic by the World Health Organization (WHO) on March 11, 2020 [2]. Infection by 34 SARS-CoV-2 causes Coronavirus Disease 2019 (COVID-19). Clinical outcomes vary widely 35 36 amongst patients [3-5]. Common symptoms of COVID-19 include fever, cough, fatigue, slight dyspnoea, sore throat, headache, conjunctivitis and gastrointestinal issues [6.7]. Patients with 37 more severe cases of COVID-19 experience respiratory failure and pneumonia that may be 38 39 deadly [8]. Current research suggests that patients with existing comorbidities, such as hypertension, cardiovascular disease, diabetes, or obesity are more likely to develop severe 40 41 COVID-19 [9-11]. COVID-19 has also been known to induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism (VTE) [12-14]. Development of cardiovascular 42 damage has been attributed to cytokine storms triggered by SARS-CoV-2 infection that can cause 43 44 multi-organ damage [15,16]. In addition, COVID-19 patients experience coagulation abnormalities, which may lead to increased risk of thromboembolic events [17]. In all, current 45 research suggests a link between cardiovascular disease and COVID-19. However, how 46 cardiovascular disease results in poorer COVID-19 prognosis and higher mortality rates remains 47 unclear. 48

49 Cardiomyopathy is a cardiovascular disease where the heart muscles become inflamed. making it difficult for the heart to pump blood throughout the body. One of the most common forms 50 51 of cardiomyopathy is dilated cardiomyopathy (DCM), where the ventricles of the heart are 52 enlarged [18]. The primary cause of DCM is unclear. However, DCM can be caused by viral infections that target the heart muscles and can thereby cause heart attacks or coronary artery 53 disease. When DCM is induced by a heart attack or coronary artery disease it is known as 54 55 ischemic cardiomyopathy (ICM). By promoting an inflammatory milieu and fibrosis, cytokines and inflammasomes play a role in cardiomyopathy pathogenesis, which suggests a potential 56 connection between cardiomyopathy and COVID-19 [19-21]. 57

VTE includes both deep vein thrombosis (DVT), where a blood clot forms in a deep vein, 58 and pulmonary embolism (PE), where a clot dislodges and travels to the lungs via the 59 60 bloodstream, blocking pulmonary circulation. It is well-established that the immune system plays a role in DVT pathogenesis, and restriction of venous blood flow leads to the recruitment of 61 neutrophils, monocytes and platelets [22-24]. Given that higher levels of monocytes and 62 neutrophils have been observed in COVID-19 patients requiring ICU hospitalization, it is possible 63 that such pre-existing immune dysregulation in COVID-19 VTE patients makes them more likely 64 to progress to severe disease [25-27]. 65

In this project, we aim to characterize dysregulation of the immune landscape in patients 66 with cardiomyopathy, with VTE and with COVID-19. We analyzed the expression of cytokine 67 68 genes and inflammasome-related genes using RNA-sequencing data obtained from COVID-19 and cardiomyopathy patients We also analyzed the extent of immune infiltration and the 69 enrichment of immunological pathways and signatures. By comparing these features of the 70 71 immune system, we hope to gain a more comprehensive understanding of the effects of cardiovascular disease on the immune system that leave patients more vulnerable to severe 72 73 COVID-19.


74 75 **2. Results**

76 2.1 Similarities in immune-associated gene dysregulation landscape in COVID-19 and 77 cardiomyopathy samples

78 We obtained gene expression sequencing data from samples of COVID-19 patients and 79 cardiomyopathy patients and performed differential expression analysis to identify genes dysregulated between patient cohorts (edgeR, p<0.05). Gene dysregulation was determined by 80 comparing COVID-19 samples to normal samples (from patients without COVID-19) and 81 82 cardiomyopathy samples to normal samples (from patients with no major cardiovascular diseases). Cardiomyopathy samples were separated based on whether patients had ischemic or 83 dilated cardiomyopathy. The two groups were individually compared against samples from 84 85 patients with no major cardiovascular disease. Cardiomyopathy and corresponding normal samples were obtained from the left ventricle of deceased patients, while COVID-19 and 86 corresponding normal samples were platelet samples. However, we expect to capture genetic 87 material from circulating immune cells in both of these samples. 88

89 Only immune associated (IA) differentially expressed genes were retained for further analysis, in order to compare the immune profile of patients with COVID-19 to that of patients with 90 cardiomyopathy. We found that there was significant overlap between COVID-19 patient IA gene 91 expression and that of both ischemic and dilated cardiomyopathy patients. About half of the IA 92 genes dysregulated in COVID-19 are also dysregulated in either or both types of cardiomyopathy 93 (Figure 1A). We grouped these genes into cytokine-related and inflammasome-related genes. 94 95 Cytokine-related genes that are dysregulated in both cardiomyopathy patients and COVID-19 patients include chemokines (CCL3, CCL4, CXCL4, etc), interleukins or interleukin receptors 96

97 (IL15, IL20RA, etc.), or genes in the TGFB family. Inflammasome-related genes include genes in
 98 the caspase family (CASP2, CASP9, etc), MAPK-related genes, and NFkB regulators (IKBKG,
 99 NFKBIA, etc.). IA gene dysregulation is very similar between dilated and ischemic
 100 cardiomyopathies. We observed that a significant number of cytokines, interleukins, TGFB 101 related genes, and TNF-related genes were dysregulated in either types of cardiomyopathies but
 102 not in COVID-19 (Figure 1A).



103 Figure 1: Comparing ICM, DCM and COVID-19 patients. (A) Summary of commonly dysregulated cytokine and

inflammasome-related genes in COVID-19 and ICM/DCM patients. Cytokines are in blue and inflammasome-related
 genes are in red. (B) Barplots of the log2 fold change of significantly dysregulated cytokine genes in COVID-19 and
 ICM/DCM patients. (C) Heatmaps of inflammasome-related genes in COVID-19 and ICM/DCM patients. (D) Radar
 plots comparing immune cell infiltration between COVID-19 and ICM/DCM patients.

108

109 Interestingly, we found that most genes dysregulated in both COVID-19 and 110 cardiomyopathy, were dysregulated to a greater degree in COVID-19 samples than in 111 cardiomyopathy samples. This trend was observed for TGFB3, CCL4, IL15, and IL20RA in both 112 ischemic cardiomyopathy samples vs COVID-19 samples and dilated cardiomyopathy samples 113 vs. COVID-19 samples (Figure 1B). Furthermore, the expression of these dysregulated genes appeared to be very similarly dysregulated in COVID-19 samples and in corresponding healthy samples, with similar levels of gene expression for individual patients in each group and a distinct upregulation trend in COVID-19 samples (Figure 1C). In contrast, these genes' expression in cardiomyopathy samples and corresponding healthy samples are only sometimes similar, without overwhelming differences in expression levels between the two cohorts (Figure 1C). Therefore,

- we believe that these dysregulated genes are dysregulated to a greater degree in COVID-19 than in cardiomyopathy
- in cardiomyopathy.

121 The inflammasome-associated genes dysregulated in both COVID-19 and cardiomyopathy are 122 upregulated in both conditions (Figure 1C), suggesting that COVID-19 and cardiomyopathy may


- 123 upregulate inflammation through similar pathways.
- 124


125 2.2 Comparison of immune cell population abundance in COVID-19 vs. cardiomyopathy patients

126 Using Cibersortx, we inferred the percent composition of 22 different immune cell types using the gene expression profile of bulk RNA-sequencing data. We discovered that the levels of T cells 127 and B cells were unchanged in healthy vs. COVID-19 patients (Figure 1D). The most noticeable 128 change in immune cell abundance occurs in macrophages for COVID-19 patients, where M0 129 130 macrophages levels were dramatically reduced, and M1 and M2 macrophages levels were slightly increased (Figure 1D). Both ischemic and dilated cardiomyopathy elicited greater immune cell 131 abundance changes than COVID-19 did, with the changes being more pronounced for ischemic 132 133 myocardiopathy. The levels of M1 and M2 macrophages also increased in ischemic myocardiopathy, similar to what was observed for COVID-19 (Figure 1D). The levels of T and B 134 135 cell subtypes changed more dramatically in ischemic and dilated myocardiopathy than in COVID-136 19. In summary, the levels of inflammatory macrophages increased for both cardiomyopathy and COVID-19 patients, while the levels of other immune cell types did not correlate between the two 137 138 conditions.

2.3 Evaluation of canonical pathways correlated with genes dysregulated in both COVID-19 and cardiomyopathy

To obtain a deeper understanding of the functions of the dysregulated genes in COVID-19 and 141 cardiomyopathy, we correlated IA gene expression to the dysregulation of canonical biological 142 pathways, obtained from the Molecular Signatures Database (MsigDB) [28]. We analyzed genes 143 that are dysregulated in both COVID-19 and cardiomyopathy to assess if they may dysregulate 144 the common pathways in the two conditions. IRAK2, upregulated in both COVID-19 and ischemic 145 cardiomyopathy, was associated with the upregulation of the FCER1 and TP63 pathways, both 146 of which are associated with inflammation and immune activation (Figure 2A) [29,30]. IRAK2 is a 147 promoter of NFkB signaling [31]. CASP2, also upregulated in COVID-19 and cardiomyopathy, is 148 associated with the downregulation of IFIH, which is capable of recognizing viruses and inducing 149 inflammation [32]. Finally, CYLD is correlated with multiple identical pathways for both COVID-19 150 samples and ischemic cardiomyopathy samples. It is also upregulated in both COVID-19 and 151 cardiomyopathy and was found to correlate with the activation of FGFR2, an important promoter 152 153 of inflammation [33], and TXA2, a well-known gene that is upregulated in platelets (Figure 2A) [34]. CYLD itself is an inhibitor of inflammation [35]. Since the majority of correlations are between 154 IA genes and pro-inflammatory pathways and signatures, we hypothesize that CYLD may be 155 expressed as a response to attenuate excessive inflammation. We found that the overwhelming 156 majority of pathways that correlated with dysregulated genes in both COVID-19 and dilated 157 158 cardiomyopathy is associated with CYLD, and these pathways are primarily pro-plotting, pro-cell aggregation, and pro-inflammation (Figure 2B), which reinforces the possibility that CYLD is released in response to inflammation.






164

2.4 Similarities in immune-associated gene dysregulation landscape in COVID-19 and venous thromboembolism (VTE) samples

We compared the immune landscape between COVID-19 samples and blood samples from VTE 167 patients to find similarities in IA gene and pathway expression. VTE patients are further classified 168 into single occurrence VTE (single VTE) and recurrent VTE. Differential expression was 169 performed by comparing blood samples for each type of VTE against blood samples from healthy 170 controls. Compared to the similarities in IA gene dysregulated between COVID-19 and 171 cardiomyopathy, the similarities between COVID-19 and VTE are much less-pronounced. We 172 identified two cytokine-associated genes that were dysregulated in both COVID-19 and single 173 VTE (CCL4 and CD40), and one cytokine-associated gene dysregulated in both COVID-19 and 174 recurrent VTE (CCL4) (Figure 3A). CCL4 is a recruiter of immune cells, including macrophages, 175

monocytes, and T-cells [36], suggesting that both COVID-19 and VTE may experience increased
 recruitment of inflammatory immune cells. The upregulation of CCL4 is much greater in COVID 19 than in VTE, however (Figure 3B).

Two inflammasome-related genes were found to be dysregulated in VTE and COVID-19, 179 including BCL2L1 and CASP4. Both single and recurrent VTE share the same set of dysregulated 180 181 inflammasome-related genes with COVID-19. BCL2L1 is known to be highly upregulated in inflamed tissue [37], and it is upregulated in COVID-19 and both single and recurrent VTE (Figure 182 3C). CASP4 directs the noncanonical upregulation of inflammasomes [38]. Interestingly, it is 183 184 upregulated in both COVID-19 and recurrent VTE but downregulated in single VTE (Figure 3C), which potentially suggests that the gene could contribute to the development of recurrent VTE. 185 Sinale VTE COVID Recurrent VTE COVID



186

Figure 3: Comparing single VTE, recurrent VTE and COVID-19 patients. (A) Summary of commonly dysregulated cytokine and inflammasome-related genes in COVID-19 and single/recurrent VTE patients. Cytokines are in blue and inflammasome-related genes are in red. (B) Barplots of the log2 fold change of significantly dysregulated cytokine genes in COVID-19 and single/recurrent VTE patients. (C) Heatmaps of inflammasome-related genes in COVID-19 and single/recurrent VTE patients. (D) Radar plots comparing immune cell infiltration between COVID-19 and single/recurrent VTE patients.

193 2.5 Comparison of immune cell population abundance in COVID-19 vs. VTE patients

194 Comparing immune cell population abundance between COVID-19 and VTE patients, we found 195 that naïve B-cells were dramatically reduced in abundance in VTE patients, which is accompanied 196 by a slight increase in activated plasma B cells (Figure 3D). This may be a sign of adaptive 197 immune activation.

2.6 Evaluation of canonical pathways correlated with genes dysregulated in both COVID-19 and
 VTE

We adopted a similar approach as described for COVID-19 vs. cardiomyopathy to examine 200 canonical pathways correlated with dysregulated genes in both COVID-19 and VTE. BCL2L1 and 201 CASP4 are the only genes dysregulated in both COVID-19 and VTE and also correlated with the 202 203 same pathways in both patient cohorts (Figure 4A,B). BCL2L1 is upregulated in COVID-19 and both VTE cohorts (Figure 4C). However, the direction of correlation to pathways was the complete 204 opposite between COVID-19 and recurrent VTE (Figure 4D, E). The high strength of correlation 205 for each cohort suggests that BCL2L1 is involved in both COVID-19 and recurrent VTE but may 206 function in opposite ways. On the other hand, CASP4 expression was correlated with over 10 207




Figure 4: Comparing single VTE, recurrent VTE and COVID-19 patients. (**A**) Summary of common dysregulated genes correlated with pathways in single VTE and COVID-19. (**B**) Summary of common dysregulated genes correlated with pathways in recurring VTE and COVID-19. (**C**) Boxplots of CASP4 and BCL2L1 expression in COVID-19 and VTE cohorts. (**D**) Barplots showing direction of correlation between CASP4/ BCL2L1 and canonical pathways. (**E**) Enrichment plots showing BCL2L1's correlation to pathways is opposite in COVID-19 and recurrent VTE patients.

213

pathways in the same direction for both COVID-19 and recurrent VTE (Figure 4D). It is also upregulated in both COVID-19 and recurrent VTE (Figure 4C). The pathways correlated with CASP4 ranges from immune related (antigen processing and cross presentation) to general metabolism-related (ABC transporter, oxidative phosphorylation). Therefore, while it is likely that CASP4 functions similarly in COVID-19 and recurrent VTE. The precise role of CASP4 requires further investigation.

220

221 3. Discussion

222

223 In this project, we characterized the immune landscape of cardiomyopathy patients, VTE patients, 224 and COVID-19 patients, drawing parallels between COVID-19 and immune dysregulation mediated by cardiovascular disease. The overlap of numerous dysregulated IA genes between 225 226 COVID-19 patients and cardiomyopathy patients not only suggests that these patients possess similar inflammatory environments but could also explain why COVID-19 patients with 227 cardiovascular disease have higher mortality rates. Of the four genes (TGFB3, CCL4, IL15, and 228 229 IL20RA) that were more severely dysregulated in COVID-19 samples compared to cardiomyopathy patients, two have been noted to be dysregulated in COVID-19 patients: 230 231 proinflammatory cytokine CCL4 was found to be highly expressed in the bronchoalveolar lavage 232 fluid of COVID-19 patients [39], and IL-15 modulates inflammation and plays a role in viral clearance [40,41]. We also found that both cardiomyopathy and COVID-19 patients had elevated 233 234 levels of inflammatory macrophages, while T and B cell levels changed more significantly in dilated and ischemic cardiomyopathy patients compared to COVID-19 patients. This points to a 235 more robust innate immune response in COVID-19 patients, which is plausible given that research 236 237 has shown that an excessively inflammatory innate immune response coupled with an impaired adaptive immune response may lead to tissue damage in COVID-19 patients [42,43]. On the 238 239 contrary, the elevated levels of T and B cells in cardiomyopathy patients indicates a stronger adaptive immune response, which is now being considered an increasingly important factor in the 240 241 pathogenesis of cardiovascular disease [44-46].

242

We analyzed overlapping gene expression pathway dysregulation between cardiomyopathy and 243 244 COVID-19 patients in order to compare IA profiles between the two patient cohorts. The overlapping genes that displayed significant canonical pathway dysregulation between the 245 cardiomyopathy and COVID-19 cohorts are CYLD, CASP2, IKBKG and IRAK2. CASP2 and 246 247 IRAK2 are of particular interest due to their involvement in inflammation. CASP2 is a proinflammatory gene and IRAK2 promotes NFkB, which ultimately causes inflammation. Both genes 248 249 are upregulated in DCM, ICM and COVID-19, suggesting that DCM and ICM patients are more susceptible to a worse inflammatory response to COVID-19. Both IRAK2 and CASP2 are directly 250 associated with the dysregulation of inflammation pathways. For instance, IRAK2 is directly 251 252 associated with the TAP63 pathway in both ICM and DCM versus COVID-19 groups, indicating that one of the effects of IRAK2 in COVID-19 and cardiomyopathy may be increasing 253 254 inflammation. Similarly, CASP2 is directly associated with the IFIH1 signaling pathway, which is known to be pro-inflammation. Overall, the genes that overlap between cardiomyopathy and 255 COVID-19 appear to act in a pro-inflammatory manner. Increased inflammatory pathway 256 257 dysregulation may indicate a reason why cardiovascular disease patients experience much worse clinical outcomes, as several studies have shown a worse inflammatory response correlates with 258 259 severity and death in COVID-19 [47].

260

Exploring the immune-association gene dysregulation landscape relationship between VTE and COVID-19 revealed overlapping differentially expression of CCL4, CD40, BCL2L1 and CASP4. 263 Of the cytokines CCL4 and CD40, only CCL4 is commonly dysregulated in single occurring VTE. 264 recurring VTE and COVID-19 patients. CCL4 has been shown to be upregulated in COVID-19 265 patients [48] and in patients who develop cardiovascular disease [49]. Therefore, the upregulation 266 of CCL4 in both VTE and COVID-19 may suggest a mechanism by which some COVID-19 patients develop cardiovascular disease post-infection. The inflammasome-related genes 267 dysregulated in both the VTE and COVID-19 cohorts are BCL2L1 and CASP4. BCL2L1 and 268 269 CASP4 expression are closely tied to inflammatory caspases. CASP4 itself is an inflammatory 270 caspase and it promotes the secretion of pro-inflammatory cytokines [50]. Conversely, BCL2L1 271 inhibits caspase release. With both of these genes being upregulated in VTE and COVID-19, future analysis must be done to examine how these genes function differently in VTE and COVID-272 273 19. BCL2L1 and CASP4, both inflammasome-related genes, stood out as the most interesting 274 genes as both displayed significant canonical pathways in both VTE groups, single occurring and 275 recurrent VTE, and COVID-19. However, only in recurring VTE did both BCL2L1 and CASP4 display overlapping canonical pathways with COVID-19, while single occurring VTE only had 276 BCL2L1 with overlapping canonical pathways with COVID-19. Most notably, in both COVID-19 277 278 and single occurring VTE, BCL2L1 expression is negatively correlated to canonical pathway 279 expression, but in recurring VTE they are positively correlated. Thus, we may deduce that a main 280 difference between single and recurrent VTE is the utilization of BCL2L1. The downregulation of BCL2L1 may increase the risk of COVID-19. due to BCL2L1-mediated inhibition of pro-281 282 inflammatory caspases. CASP4, on the other hand, only has overlapping significant canonical pathways with COVID-19 in the recurrent VTE cohort. From these overlapping canonical 283 pathways, we could not find a common trend like there was in BCL2L1. However, we could 284 285 deduce from these pathways that CASP4 functions similarly in both recurrent VTE and COVID-286 19.

287

In conclusion, our study demonstrates that cardiomyopathy and VTE patients display a significant 288 289 overlap of inflammasome gene expression profiles with that of COVID-19 patients. This may 290 explain why patients with cardiovascular disease are more likely to develop severe COVID-19, and tend to have poorer clinical outcomes [51,52]. Furthermore, we have found that patients with 291 292 cardiomyopathy display more similar immune dysregulation to COVID-19 patients than VTE patients, which may indicate that COVID-19 patients who have cardiomyopathy are at higher risk. 293 of severe COVID-19 than COVID-19 patients with VTE. Our findings also suggest that 294 295 investigating the relationships between different cardiovascular diseases and COVID-19 disease severity and mortality may be meaningful, and can offer greater insight into COVID-19 immune 296 297 dysregulation. However, we recognize our study has several limitations. We had limited COVID-298 19 platelet data, specifically normal patients. Thus, our differential expression analysis may have been impacted, and the statistical power of our analysis is reduced. However, the direction of 299 300 dysregulation of many of the genes we identified were consistent with existing literature. 301 Additionally, we used platelet data, instead of blood samples. In order to validate our results, in vitro and in vivo experiments can be done in the future. Despite these limitations, we believe our 302 study advances our understanding of the relationship between cardiovascular disease and 303 COVID-19. 304

305

306 4. Methods and Materials

307 Downloading Data

RNA-sequencing data was obtained from the following datasets: GSE116250, GSE19151 and SRP262885 (8) [53-55]. GSE116250, provided by Sweet et. al, consists of RNA-sequencing of human left ventricular samples from 14 patients with no major cardiac history (non-failing), 37 patients with dilated cardiomyopathy and 13 patients with ischemic cardiomyopathy. The mean age of patients with dilated and ischemic cardiomyopathy was 49 and 56 years respectively. GSE19151, provided by Lewis et. al, consists of high-throughput sequencing of whole blood samples from 63 healthy controls, 23 patients with single event VTE, 17 patients with recurrent event VTE on warfarin. The mean age of patients with single VTE and recurrent VTE was 43.8 and 55.7 years respectively. Lastly, SRP262885 consists of RNA-sequencing data of platelets from 10 COVID-19 subjects and 5 healthy controls. The mean age of COVID-19 patients and healthy controls is 51.1 and 43.8 respectively.

319

320 Differential Expression

Differential expression analysis was employed to compare the expression of genes between diseased and normal individuals. For the cardiomyopathy and venous thrombosis cohorts, a Kruskal-Wallis analysis test was used to determine the differentially expressed genes, and genes with p < 0.05 were considered significantly dysregulated. Differential expression was applied to the COVID-19 platelet data to determine the genes that were differentially expressed (p < 0.05).

- 327
- 328 GSEA

To correlate gene expression to immune-associated signatures, Gene Set Enrichment Analysis (GSEA) was utilized. Pathways were chosen from the C2:CP set of signatures from the Molecular Signatures Database [28]. Signatures that were significantly enriched were those with a nominal p-value < 0.05.

333

334 CIBERSORTx

The CIBERSORTx algorithm was used to deconvolute RNA-sequencing data to estimate the infiltration levels of 22 immune cell types [56]. These immune cell types include: naïve B-cells, memory B-cells, plasma cells, CD8 T-cells, CD4 naïve T-cells, CD4 memory resting T-cells, CD4 memory activated T-cells, follicular helper T-cells, regulatory T-cells, gamma-delta T-cells, resting NK cells, activated NK cells, monocytes, M0-M2 macrophages, resting dendritic cells, activated dendritic cells, resting mast cells, activated mast cells, eosinophils, and neutrophils.

341

Author Contributions: Conceptualization, W.M.O; methodology, W.T.L and W.M.O.; software, N/A; formal analysis, A.C.L, G.C, and C.C; investigation, A.L. and G.C.; resources, W.M.O.; data curation, N/A; writing, A.C.L., G.C. and W.T.L.; visualization, A.L. and G.C.; supervision W.M.O.; project administration, W.M.O.; funding acquisition, W.M.O.

Funding: This research was funded the University of California, Office of the President/Tobacco-Related Disease Research Program Emergency COVID-19 Research Seed Funding Grant (Grant

number: R00RG2369) to W.M.O. and the University of California, San Diego Academic Senate
 Grant (Grant number: RG096651) to W.M.O.

350 **Conflicts of Interest:** The authors declare no conflict of interest.

351352 References

- Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China,
 N Engl J Med 2020;382(8):727–733.
- World Health Organization Regional Office For Europe. (2020). Retrieved from https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, Department of Pathology, Pathology Service, VA
 San Diego Healthcare System San Diego, University of California San Diego, La Jolla, CA
 92093, USAJ., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y.,
- 359 92093, USAJ., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., 260 Mu, W. Xia, X. Xia, W. Li, H. Liu, M. Xiaa, Y. Cao, P. (2020). Clinical features of
- 360 Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., ... Cao, B. (2020). Clinical features of
- 361 patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England),
- 362 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5


4. Liu, K., Fang, Y., Deng, Y., Liu, W., Wang, M., & Ma, J. et al. (2020). Clinical characteristics 363 of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal, 364 133(9), 1025-1031. https://doi.org/10.1097/cm9.000000000000744 365 366 5. Xu XW, Wu XX, Jiang XG, et al. . Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case studies. 367 368 BMJ 2020; 368: m606. doi:10.1136/bmj.m606 369 6. Chen N, Zhou M, Dong X et al Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 370 371 395: 507–13 372 7. Yang X, Yu Y, Xu J et al Clinical course and outcomes of critically ill patients with SARS-373 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 374 Lancet Resp Med 2020; 8: 475-81. 8. Gibson P, Qin L, Puah S. COVID -19 acute respiratory distress syndrome (ARDS): clinical 375 features and differences from typical pre- COVID -19 ARDS. Medical Journal of Australia. 376 377 2020;213(2):54. doi:10.5694/mja2.50674 378 9. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected 379 with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious 380 Diseases. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017 10. Pranata R, Huang I, Lim M, Wahjoepramono E, July J. Impact of cerebrovascular and 381 cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-382 analysis, and meta-regression. Journal of Stroke and Cerebrovascular Diseases. 383 384 2020;29(8):104949. doi:10.1016/j.jstrokecerebrovasdis.2020.104949 11. Tian W, Jiang W, Yao J et al. Predictors of mortality in hospitalized COVID-19 patients: A 385 systematic review and meta-analysis. J Med Virol. 2020. doi:10.1002/jmv.26050 386 387 12. Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-388 19 in Wuhan, China. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.0950 (2020). 13. Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus 389 390 disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1017 391 (2020). 14. Shi, S. et al. Characteristics and clinical significance of myocardial injury in patients with 392 severe coronavirus disease 2019. Eur. Heart J. 41, 2070-2079 (2020). 393 394 15. Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363-374 (2020 395 396 16. Vaninov, N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 2020, 397 10.1038/s41577-020-0305-6, doi:10.1038/s41577-020-0305-6. 398 17. Connors, J.M. and Levy, J.H. (2020), Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost, 18: 1559-1561. doi:10.1111/jth.14849 399 400 18. National Center for Health Statistics, & Centers for Disease Control and Prevention. (2020). Retrieved from https://www.cdc.gov/heartdisease/cardiomyopathy.htm 401 19. Rose, Noel R. "Critical cytokine pathways to cardiac inflammation." Journal of interferon & 402 403 cytokine research : the official journal of the International Society for Interferon and Cytokine 404 Research vol. 31,10 (2011): 705-10. doi:10.1089/jir.2011.0057 405 20. An, Na et al. "Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-406 Inflammatory Marker in Cardiovascular Diseases." Frontiers in immunology vol. 10 1592. 10 407 Jul. 2019, doi:10.3389/fimmu.2019.01592


408	1. Cheng Z., et al. NLRP3 inflammasome-mediated pyre	
409	of non-ischemic dilated cardiomyopathy. Redox Biolo	ogy vol 34. 2020, doi:
410	https://doi.org/10.1016/j.redox.2020.101523.	
411	2. von Bruhl M.L. Monocytes, neutrophils, and platelets	
412	venous thrombosis in mice in vivo. J. Exp. Med. 2012	2;209:819–835.
413	3. Brill A. Neutrophil extracellular traps promote deep ve	ein thrombosis in mice. J. Thromb.
414	Haemost. 2012;10:136–144.	
415	4. Fuchs T.A. Neutrophil extracellular trap (NET) impact	t on deep vein thrombosis. Arterioscler.
416	Thromb. Vasc. Biol. 2012;32:1777-	
417	5. Zhou, Y. et al. Pathogenic T cells and inflammatory n	nonocytes incite inflammatory storm in
418	severe COVID-19 patients. Natl Sci. Rev. https://doi.org/	org/10.1093/nsr/nwaa041 (2020).
419	6. Zhang, D. et al. COVID-19 infection induces readily c	letectable morphological and
420	inflammation-related phenotypic changes in periphera	al blood monocytes, the severity of
421	which correlate with patient outcome. Preprint at mec	IRxiv
422	https://doi.org/10.1101/2020.03.24.20042655 (2020).	
423	7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Cl	inical characteristics of 138 hospitalized
424	patients with 2019 novel coronavirus-infected pneum	onia in Wuhan, China. JAMA. (2020)
425	323:1061–9. doi: 10.1001/jama.2020.1585	
426	8. Liberzon A, Subramanian A, Pinchback R, Thorvalds	dottir H, Tamayo P, Mesirov JP:
427	Molecular signatures database (MSigDB) 3.0. Bioi	nformatics 2011, 27 (12):1739-1740.
428	9. Shin JS, Greer AM. The role of FccRI expressed in d	endritic cells and monocytes. Cell Mol
429	Life Sci. 2015;72(12):2349-2360. doi:10.1007/s00018	3-015-1870-x
430	0. Mehta SY, Morten BC, Antony J, et al. Regulation of	the interferon-gamma (IFN-γ) pathway
431	by p63 and Δ 133p53 isoform in different breast cance	er subtypes. Oncotarget.
432	2018;9(49):29146-29161. Published 2018 Jun 26. do	i:10.18632/oncotarget.25635
433	1. Keating S, Maloney G, Moran E, Bowie A. IRAK-2 Pa	0
434	Signaling Pathways to NFkB via Activation of TRAF6	
435	Chemistry. 2007;282(46):33435-33443. doi:10.1074/	
436	2. Weber M, Gawanbacht A, Habjan M, et al. Incoming	RNA virus nucleocapsids containing a
437	5'-triphosphorylated genome activate RIG-I and antiv	
438	2013;13(3):336-346. doi:10.1016/j.chom.2013.01.012	
439	3. Wang C, Liu Z, Ke Y, Wang F: Intrinsic FGFR2 and	
440	Prostate and Prostate Cancer. Front Genet 2019, 1	0 :12.
441	4. Hamanaka N. Eicosanoids in Mammals. Comprehens	
442	1999:159-206. doi:10.1016/b978-0-08-091283-7.001	-
443	5. Mukherjee S, Kumar R, Tsakem Lenou E, Basrur V, I	Kontoviannis DL, Ioakeimidis F,
444	Mosialos G, Theiss AL, Flavell RA, Venuprasad K: D	
445	inflammasome by Cyld critically regulates intesti	-
446	21 (6):626-635.	
447	6. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Sch	einecker C. Germain RN: Chemokines
448	enhance immunity by guiding naive CD8+ T cells	-
449	interaction. <i>Nature</i> 2006, 440 (7086):890-895.	
450	7. Szauter KM, Jansen MK, Okimoto G, Loomis M, Kim	ura JH, Heller M, Ku T. Tiirikainen M.
451	Boyd CD, Csiszar K <i>et al</i> : Persistent Inflammatory	
452	Onset Myocardial Infarction in a Medicated Multie	
453	Insights 2011, 4 .	

- 38. Casson CN, Yu J, Reyes VM, Taschuk FO, Yadav A, Copenhaver AM, Nguyen HT, Collman
 RG, Shin S: Human caspase-4 mediates noncanonical inflammasome activation
 against gram-negative bacterial pathogens. *Proceedings of the National Academy of Sciences* 2015, 112(21):6688-6693.
- 458 39. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid
 459 and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect.
 460 2020;9(1):761-770. doi:10.1080/22221751.2020.1747363
- 40. H.K. Kandikattu, S. Upparahalli Venkateshaiah, A. Mishra. Synergy of Interleukin (IL)-5 and
 IL-18 in eosinophil mediated pathogenesis of allergic diseases. Cytokine Growth Factor
 Rev., 47 (2019), pp. 83-98
- 464 41. K.C. Verbist, K.D. Klonowski. Functions of IL-15 in anti-viral immunity: multiplicity and
 465 variety. Cytokine, 59 (3) (2012), pp. 467-478
- 466 42. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
 467 China. Lancet Lond. Engl. 395, 497–506 (2020).
- 468 43. Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress
 469 syndrome. Lancet Respir. Med. 8, 420–422 (2020).
- 44. Bansal SS, Ismahil MA, Goel M, et al. Activated T Lymphocytes are Essential Drivers of
 Pathological Remodeling in Ischemic Heart Failure. Circ Heart Fail. 2017;10(3):e003688.
 doi:10.1161/CIRCHEARTFAILURE.116.003688
- 473 45. Bansal SS, Ismahil MA, Goel M, et al. Dysfunctional and Proinflammatory Regulatory T474 Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.
 475 Circulation. 2019;139(2):206-221. doi:10.1161/CIRCULATIONAHA.118.036065
- 476 46. Blanton RM, Carrillo-Salinas FJ, Alcaide P. T-cell recruitment to the heart: friendly guests or 477 unwelcome visitors?. Am J Physiol Heart Circ Physiol. 2019;317(1):H124-H140.
 478 doi:10.1152/ajpheart.00028.2019
- 479 47. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for
 480 monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).
- 48. Yong Xiong, Yuan Liu, Liu Cao, Dehe Wang, Ming Guo, Ao Jiang, Dong Guo, Wenjia Hu,
 48. Jiayi Yang, Zhidong Tang, Honglong Wu, Yongquan Lin, Meiyuan Zhang, Qi Zhang, Mang
 483 Shi, Yingle Liu, Yu Zhou, Ke Lan & Yu Chen (2020) Transcriptomic characteristics of
 484 bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients,
 485 Emerging Microbes & Infections, 9:1, 761-770, DOI: 10.1080/22221751.2020.1747363
- 486 49. Chang TT, Chen JW. Emerging role of chemokine CC motif ligand 4 related
 487 mechanisms in diabetes mellitus and cardiovascular disease: friends or foes?.
 488 *Cardiovasc Diabetol.* 2016;15(1):117. Published 2016 Aug 24.
- 489 doi:10.1186/s12933-016-0439-9
- 490 50. Papoff, G., Presutti, D., Lalli, C. *et al. CASP4* gene silencing in epithelial cancer
 491 cells leads to impairment of cell migration, cell-matrix adhesion and tissue
- 492 invasion. *Sci Rep* 8, 17705 (2018). <u>https://doi.org/10.1038/s41598-018-35792-8</u>
- 493 51. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation.
 494 2020;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941
- 495 52. Madjid, M., Safavi-Naeini, P., Solomon, S. D. & Vardeny, O. Potential effects of
 496 coronaviruses on the cardiovascular system: a review. JAMA Cardiol.
 497 https://doi.org/10.1001/jamacardio.2020.1286 (2020).

- 498 53. Sweet ME, Cocciolo A, Slavov D, Jones KL et al. Transcriptome analysis of human heart failure reveals
 499 dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart
 500 failure. *BMC Genomics* 2018 Nov 12;19(1):812. PMID: <u>30419824</u>
- 501 54. Sweet ME, Cocciolo A, Slavov D, Jones KL et al. Transcriptome analysis of human heart failure reveals
 502 dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart
 503 failure. *BMC Genomics* 2018 Nov 12;19(1):812. PMID: <u>30419824</u>
- 504 55. RNA-seq of platelets from SARS-CoV-2 Covid-19. University of Utah 2020 May 22. Doi: 505 trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP262885
- 506 56. Chen, B.; Khodadoust, M.S.; Liu, C.L.; Newman, A.M.; Alizadeh, A.A. Profiling Tumor
 507 Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol 2018, 1711, 243–259,
 508 doi:10.1007/978-1-4939-7493-1_12.


A	ICM	COVID	DCM	COVID	Cytokines
	LIPR LIPR LIPR LI11 LI11RA CCL21 LI11RA CCL22 CCL22 CCL24 TRAF6 CCL22 TAB3 CCL24 TRAF6 CCL3 CASP2 CCL4 CASP9 CCL4 CASP9 CCL4 CASP9 CCL3 CCL3 CCL3 CCL3 CASP2 CCL4 CASP9 CCL3 CCL3 CASP9 CCL4 CASP9 CCL3 CCL3 CASP2 CCL4 CASP9 CCL4 CASP9 CCL3 CCL3 HSP90AB1 KBKB IL17 CASC1 IL17 CD27 CXCL1 IL17 TNFSF12 IL17 TNFSF13 IL18 CXCL1 IL18 IL23 CXCL1 IL18 IL23 CXCL14 IL18 IL2 IL5 RAK2 NFKBIB TBR NOD1 TNFAIP3 TRIP6 IL27 CXCL16 IL33 CXCL9 TNFSF9 IL27 CXCL2 IL33 CXCL9 TNFS IL34 CXCR2 IL34 CXCR4 CL5 CL3 CASP2 CCL3 CASP2 CCL3 CASP2 CCL3 CASP2 CCL3 CASP2 CCL3 CASP2 CASP3 CASP2 CL4 CASP9 CASP3 CXCL3 HSP00AB1 IL5 IL5 IL20 IL3 CXCR1 IL18 TBR NOD1 TNFAIP3 TRIP6	CCL2 CKLF CXCL5 EPOR IL15RA IL1RN IL20RB TGFB1 TGFBR2 CCL2 CKLF IRAK1 MAPK10 MAPK10 MAPK13 MAPK13 MAPK14 MAPK3 MAPK3 MAPK3 TAB3 TRAF6 NAIP NFKBIA POLR2J4 PSTPIP1 RELA SUGT1 TAB1 TMEM189 TXN TXNIP UBE2N	OSIVIRIL10CCR4NLRP1CCTGFB2IL11CCR7NLRP3CXTGFBR1IL11RACD27PYCARDIL1	CL3 CL4 XCL3 15 20RA FFB3 CL4 XCL3 IS 20RB GFB3 CL2L1 CARD6 CASP4 CASP9 CYLD HSP90AB1 IKBKG MAPK12 NOD1 TRIP6 TXNIP CL2L1 CARD6 CASP4 CASP8 CHUK HSP90B1 IL1RN LTB TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 CCL2 CKLF IL15RA TGFB1 TAB1 TAB3 TNAIP	Inflammasome related genes








Single VTE	COVID	Recurrent VTE	COVID
CD27 BCL2 CXCL10 CASP5	CCL4 CCL2 CCL3 CCL3 CKLF CCL3 CKLF CCL3 CKLF CCL3 CKLF CCL3 CXCL3 CXCL3 CXCL3 CXCL3 CXCL3 CXCL5 MAPK10 CARD6 CARD6 CASP2 CXCL5 MAPK13 CASP8 TAB1 CASP8 TAB3 CASP9 TMEM189 CHUK TNFAIP3 CYLD TRAF6 TRIP6 TXN TXNIP UB2N HSP90A1 TRAF6 TXN TXNIP UB2N KBKB CYLD TRAF6 TXN TXNIP UB2N CHUK TNPAIP3 CHUK TNFAIP3 CYLD TRAF6 TXN TXNIP UB2N TAB1 CASP9 TMEM189 CHUK TNFAIP3 CYLD TRAF6 TXN TXNIP UB2N TXNIP UB2N TAB1 CASP9 CHUK TNFAIP3 CYLD TRAF6 TXN TXNIP UB2N TAB1 CASP9 TMEM189 CHUK TNFAIP3 TXN TXNIP UB2N TAB1 CASP9 TMEM189 CHUK TNFAIP3 TXNIP UB2N TAB1 TAB3 CYLD TRAF6 TXN TXNIP UB2N TAB1 TAB3 CYLD TRAF6 TXN TXNIP UB2N TAB1 TAB3 TAB3 CYLD TRAF6 TXN TXNIP UB2N TAB1 TAB3 TAB3 CYLD TRAF6 TXN TXNIP UB2N TAB1 TAF5 TXN TXNIP UB2N TAB1 TAF5 TXN TXNIP UB2N TAB1 TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TAB1 TXN TXNIP TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TAB1 TXN TXNIP TXNIP TAF5 TXNIP TXNIP TAF5 TXN TXNIP TXNIP TAF5 TAB1 TXN TXNIP TXNIP TXNIP TAF5 TAB1 TXNIP TXNIP TXNIP TAF5 TAB1 TXN TXNIP TXNIP TXNIP TAF5 TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TAF5 TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TAF5 TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TXNIP TAF5 TXNIP T	CD27 CXCL10 BIRC2 CCL4 CXCL8 CARD8 IFNG CASP5 BCL2L1 IL13 IL18 CASP4 IL16 IL18 IL1A NLRP3 IL3 MAPK1 TNFSF10 MAPK9 RELA	CCL2 MAPK1 CCL3 MAPK9 CD40 RELA BIRC3 CKLF MAPK10 CARD6 CXCL3 MAPK12 CASP2 TAB1 CXCL5 MAPK13 CASP8 TAB3 CXCR1 MAPK13 CASP8 TAB3 CXCR1 MAPK3 CHUK TNFAIP3 POR MAPK3 CYLD TNFAIP3 LI5 NAIP HSP90AA1 TRAF6 TNFAIP3 LI20RA NFKBIA HSP90B1 TKAF6 TXN LI20RA NFKBIB HSP90B1 KBK6 TMBK SUGT1 KBKB SUGT1 RAK1 TGFB1 TGFB1 TGFB1

CCL4












Α

В

3.5









COVID-19 Platelet

DCM

D POOFEE PATH

DCM and COVID-19: Overlapping Pathway Enrichment Scores





в

A

Enrichment Score